A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Clinical trial NCT06744920 · RECRUITING

Trial details

NCT number: NCT06744920
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Generalized Myasthenia Gravis

Start date: 2025-02-07
Primary completion: 2028-02-25
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.